US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US5433081A
(en)
*
|
1993-01-22 |
1995-07-18 |
Major; Thomas O. |
Refrigerant recovery and purification method and apparatus with oil adsorbent separator
|
DE69433036T2
(en)
|
1993-09-03 |
2004-05-27 |
Isis Pharmaceuticals, Inc., Carlsbad |
AMINODERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES
|
US5502177A
(en)
*
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US5854033A
(en)
|
1995-11-21 |
1998-12-29 |
Yale University |
Rolling circle replication reporter systems
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
WO2005121371A2
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20040033973A1
(en)
*
|
2002-08-16 |
2004-02-19 |
Muthiah Manoharan |
Compounds and oligomeric compounds comprising novel nucleobases
|
US6111085A
(en)
*
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
US6617422B1
(en)
|
1997-05-23 |
2003-09-09 |
Peter Nielsen |
Peptide nucleic acid monomers and oligomers
|
AU731909B2
(en)
|
1997-07-01 |
2001-04-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US7572582B2
(en)
*
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
US6007992A
(en)
*
|
1997-11-10 |
1999-12-28 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US6028183A
(en)
|
1997-11-07 |
2000-02-22 |
Gilead Sciences, Inc. |
Pyrimidine derivatives and oligonucleotides containing same
|
US20040186071A1
(en)
*
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
AU745880B2
(en)
*
|
1998-05-21 |
2002-04-11 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
JP2002515514A
(en)
*
|
1998-05-21 |
2002-05-28 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
Compositions and methods for local delivery of oligonucleotides
|
WO2000001393A2
(en)
*
|
1998-07-02 |
2000-01-13 |
The Trustees Of Columbia University In The City Of New York |
OLIGONUCLEOTIDE INHIBITORS OF bcl-xL
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US6127124A
(en)
*
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US20040081959A9
(en)
*
|
1999-12-08 |
2004-04-29 |
Epoch Biosciences, Inc. |
Fluorescent quenching detection reagents and methods
|
US6727356B1
(en)
|
1999-12-08 |
2004-04-27 |
Epoch Pharmaceuticals, Inc. |
Fluorescent quenching detection reagents and methods
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US20060166227A1
(en)
*
|
2000-06-20 |
2006-07-27 |
Stephen Kingsmore |
Protein expression profiling
|
US6323009B1
(en)
*
|
2000-06-28 |
2001-11-27 |
Molecular Staging, Inc. |
Multiply-primed amplification of nucleic acid sequences
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
WO2002030465A2
(en)
|
2000-10-12 |
2002-04-18 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7226739B2
(en)
|
2001-03-02 |
2007-06-05 |
Isis Pharmaceuticals, Inc |
Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
|
US7666588B2
(en)
|
2001-03-02 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
|
US20030027135A1
(en)
|
2001-03-02 |
2003-02-06 |
Ecker David J. |
Method for rapid detection and identification of bioagents
|
US20040121311A1
(en)
*
|
2002-12-06 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in livestock
|
US20040121310A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in forensic studies
|
US20040121314A1
(en)
*
|
2002-12-06 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in containers
|
US7718354B2
(en)
*
|
2001-03-02 |
2010-05-18 |
Ibis Biosciences, Inc. |
Methods for rapid identification of pathogens in humans and animals
|
ATE434936T1
(en)
|
2001-03-14 |
2009-07-15 |
Myriad Genetics Inc |
TSG101-GAG INTERACTION AND THEIR USE
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
DK2000545T3
(en)
|
2001-06-20 |
2011-11-28 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of lung tumor
|
CA2451643C
(en)
|
2001-06-21 |
2012-11-13 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US7217510B2
(en)
*
|
2001-06-26 |
2007-05-15 |
Isis Pharmaceuticals, Inc. |
Methods for providing bacterial bioagent characterizing information
|
US8073627B2
(en)
|
2001-06-26 |
2011-12-06 |
Ibis Biosciences, Inc. |
System for indentification of pathogens
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
EP2174953A1
(en)
|
2001-09-18 |
2010-04-14 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
AU2002367318B2
(en)
|
2002-01-02 |
2007-07-12 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7553619B2
(en)
*
|
2002-02-08 |
2009-06-30 |
Qiagen Gmbh |
Detection method using dissociated rolling circle amplification
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
WO2003100035A2
(en)
*
|
2002-04-01 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Method for rapid detection and identification of viral bioagents
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
JP2005536190A
(en)
|
2002-04-16 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
Compositions and methods for tumor diagnosis and treatment
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US20040092470A1
(en)
*
|
2002-06-18 |
2004-05-13 |
Leonard Sherry A. |
Dry powder oligonucleotide formualtion, preparation and its uses
|
EP2116604A1
(en)
|
2002-08-05 |
2009-11-11 |
University of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
EP2322535A3
(en)
|
2002-09-20 |
2011-09-28 |
Yale University |
Riboswitches, methods for their use, and compositions for use with riboswitches
|
JP4694201B2
(en)
*
|
2002-09-20 |
2011-06-08 |
インテグレイテッド ディーエヌエイ テクノロジーズ インコーポレイテッド |
Anthraquinone quenching dyes, their production and use
|
US7229976B2
(en)
|
2002-09-26 |
2007-06-12 |
Isis Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
EP1560597A4
(en)
*
|
2002-10-29 |
2007-06-27 |
Pharmacia Corp |
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
AU2003287505A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US9150606B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
AU2003290598A1
(en)
*
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
ES2420914T3
(en)
|
2002-11-13 |
2013-08-27 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
CA2506127C
(en)
|
2002-11-15 |
2013-07-09 |
Morphotek, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
US8007804B2
(en)
|
2002-11-15 |
2011-08-30 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
EP2410332A1
(en)
|
2002-11-21 |
2012-01-25 |
The University Of Utah |
Method for identifying purinergic modulators of the olfactory system
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
JP2006516193A
(en)
|
2002-12-06 |
2006-06-29 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
Rapid identification of pathogens in humans and animals
|
US20040121315A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in containers thereby
|
US20040122857A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent in forensic studies thereby
|
US20040121312A1
(en)
*
|
2002-12-18 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of the absence of bioagents
|
WO2004058987A2
(en)
|
2002-12-20 |
2004-07-15 |
Qiagen Gmbh |
Nucleic acid amplification
|
US9487823B2
(en)
*
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
US6977153B2
(en)
*
|
2002-12-31 |
2005-12-20 |
Qiagen Gmbh |
Rolling circle amplification of RNA
|
US7468356B2
(en)
|
2003-02-11 |
2008-12-23 |
Antisense Therapeutics Ltd. |
Modulation of insulin like growth factor I receptor expression
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US8043834B2
(en)
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
US20040198640A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US8046171B2
(en)
*
|
2003-04-18 |
2011-10-25 |
Ibis Biosciences, Inc. |
Methods and apparatus for genetic evaluation
|
US8057993B2
(en)
|
2003-04-26 |
2011-11-15 |
Ibis Biosciences, Inc. |
Methods for identification of coronaviruses
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US8158354B2
(en)
|
2003-05-13 |
2012-04-17 |
Ibis Biosciences, Inc. |
Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
US7964343B2
(en)
*
|
2003-05-13 |
2011-06-21 |
Ibis Biosciences, Inc. |
Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
US7276599B2
(en)
*
|
2003-06-02 |
2007-10-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
US7786290B2
(en)
|
2003-06-13 |
2010-08-31 |
Alnylam Pharmaceuticals, Inc. |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
EP1636342A4
(en)
*
|
2003-06-20 |
2008-10-08 |
Isis Pharmaceuticals Inc |
Oligomeric compounds for use in gene modulation
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
PT1660057E
(en)
|
2003-08-27 |
2012-08-02 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
US20050053981A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
US20100035239A1
(en)
*
|
2003-09-11 |
2010-02-11 |
Isis Pharmaceuticals, Inc. |
Compositions for use in identification of bacteria
|
US20060240412A1
(en)
*
|
2003-09-11 |
2006-10-26 |
Hall Thomas A |
Compositions for use in identification of adenoviruses
|
US8546082B2
(en)
|
2003-09-11 |
2013-10-01 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
US8097416B2
(en)
|
2003-09-11 |
2012-01-17 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
US20080138808A1
(en)
*
|
2003-09-11 |
2008-06-12 |
Hall Thomas A |
Methods for identification of sepsis-causing bacteria
|
US20120122101A1
(en)
*
|
2003-09-11 |
2012-05-17 |
Rangarajan Sampath |
Compositions for use in identification of bacteria
|
NZ545134A
(en)
|
2003-09-18 |
2009-06-26 |
Lilly Co Eli |
Modulation of eIF4E expression
|
AU2004274021B2
(en)
*
|
2003-09-18 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
EP1678194B1
(en)
|
2003-10-10 |
2013-06-26 |
Alchemia Oncology Pty Limited |
The modulation of hyaluronan synthesis and degradation in the treatment of disease
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
US7439341B2
(en)
|
2003-11-14 |
2008-10-21 |
Integrated Dna Technologies, Inc. |
Fluorescence quenching azo dyes, their methods of preparation and use
|
ES2493016T3
(en)
|
2003-11-17 |
2014-09-11 |
Genentech, Inc. |
Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or a cytotoxic agent and methods for the treatment of tumors of hematopoietic origin
|
US8163895B2
(en)
|
2003-12-05 |
2012-04-24 |
Ibis Biosciences, Inc. |
Compositions for use in identification of orthopoxviruses
|
JP2007520222A
(en)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
Regulation of glucocorticoid receptor expression
|
US8778900B2
(en)
*
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
US7468431B2
(en)
*
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
ATE447024T1
(en)
*
|
2004-02-06 |
2009-11-15 |
Dharmacon Inc |
STABILIZED RNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
US7666592B2
(en)
|
2004-02-18 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for concurrent identification and quantification of an unknown bioagent
|
US8119336B2
(en)
|
2004-03-03 |
2012-02-21 |
Ibis Biosciences, Inc. |
Compositions for use in identification of alphaviruses
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
KR101147147B1
(en)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Modified polynucleotides for reducing off-target effects in rna interference
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
EP2540734B1
(en)
|
2004-04-05 |
2016-03-30 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
US20050260755A1
(en)
*
|
2004-04-06 |
2005-11-24 |
Isis Pharmaceuticals, Inc. |
Sequential delivery of oligomeric compounds
|
EP1750776A2
(en)
|
2004-04-30 |
2007-02-14 |
Alnylam Pharmaceuticals Inc. |
Oligonucleotides comprising a c5-modified pyrimidine
|
DK1773872T3
(en)
|
2004-05-21 |
2017-05-08 |
Uab Res Found |
VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
|
JP4810533B2
(en)
|
2004-05-24 |
2011-11-09 |
アイビス バイオサイエンシズ インコーポレイティッド |
Mass spectrometry using selective ion filtration by digital thresholding.
|
US20050266411A1
(en)
*
|
2004-05-25 |
2005-12-01 |
Hofstadler Steven A |
Methods for rapid forensic analysis of mitochondrial DNA
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
AU2004320622B2
(en)
*
|
2004-06-03 |
2012-06-14 |
Isis Pharmaceuticals, Inc. |
Chimeric gapped oligomeric compositions
|
US7811753B2
(en)
|
2004-07-14 |
2010-10-12 |
Ibis Biosciences, Inc. |
Methods for repairing degraded DNA
|
US7427675B2
(en)
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
WO2006032144A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Arc Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US20060166234A1
(en)
*
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
CA2600184A1
(en)
|
2005-03-03 |
2006-09-08 |
Isis Pharmaceuticals, Inc. |
Compositions for use in identification of adventitious viruses
|
US8084207B2
(en)
*
|
2005-03-03 |
2011-12-27 |
Ibis Bioscience, Inc. |
Compositions for use in identification of papillomavirus
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
US7476733B2
(en)
*
|
2005-03-25 |
2009-01-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
EP1863908B1
(en)
*
|
2005-04-01 |
2010-11-17 |
Qiagen GmbH |
Reverse transcription and amplification of rna with simultaneous degradation of dna
|
AU2006251637B2
(en)
*
|
2005-05-20 |
2012-06-14 |
Integrated Dna Technologies, Inc. |
Compounds and methods for labeling oligonucleotides
|
JP5329949B2
(en)
|
2005-05-31 |
2013-10-30 |
エコーレ ポリテクニーク フェデラーレ デ ローザンヌ |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
US8252756B2
(en)
|
2005-06-14 |
2012-08-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US8026084B2
(en)
*
|
2005-07-21 |
2011-09-27 |
Ibis Biosciences, Inc. |
Methods for rapid identification and quantitation of nucleic acid variants
|
EP1929012B1
(en)
|
2005-08-11 |
2010-10-06 |
Synthetic Genomics, Inc. |
Method for in vitro recombination
|
AU2006281569A1
(en)
|
2005-08-17 |
2007-02-22 |
Medexis S.A. |
Composition and method for determination of CK19 expression
|
WO2007027775A2
(en)
|
2005-08-29 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Methods for use in modulating mir-122a
|
DE102005042073B4
(en)
*
|
2005-08-31 |
2010-11-11 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
fiber laser
|
EP1762627A1
(en)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Method for the activation of a nucleic acid for performing a polymerase reaction
|
EA200800868A1
(en)
|
2005-09-19 |
2008-10-30 |
ДЖОНСОН ЭНД ДЖОНСОН ФАРМАСЬЮТИКАЛ РИСЕРЧ ЭНД ДИВЕЛОПМЕНТ, Эл. Эл. Си. |
MODULATION OF THE GLUCOCORTICOID RECEPTOR EXPRESSION
|
EP2096170B1
(en)
|
2005-09-19 |
2011-08-10 |
Isis Pharmaceuticals, Inc. |
Modulation of glucagon receptor expression
|
EP2189522A1
(en)
|
2005-10-14 |
2010-05-26 |
MUSC Foundation For Research Development |
Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EP2325315B1
(en)
|
2005-10-28 |
2014-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
WO2007056331A2
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
EP1966377A2
(en)
|
2005-11-21 |
2008-09-10 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
JP2009524411A
(en)
*
|
2005-12-21 |
2009-07-02 |
イェール ユニバーシティー |
Methods and compositions related to the regulation of riboswitches
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
JP5213723B2
(en)
|
2006-01-27 |
2013-06-19 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Oligomer compounds and compositions for use in modulating microRNA
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
JP5342881B2
(en)
|
2006-01-27 |
2013-11-13 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
6-modified bicyclic nucleic acid analogues
|
CA2873833A1
(en)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
WO2007125173A2
(en)
*
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
DE102006020885A1
(en)
*
|
2006-05-05 |
2007-11-08 |
Qiagen Gmbh |
Inserting a tag sequence into a nucleic acid comprises using an anchor oligonucleotide comprising a hybridizing anchor sequence and a nonhybridizing tag-template sequence
|
WO2007134014A2
(en)
*
|
2006-05-05 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of gcgr
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
ES2389737T3
(en)
*
|
2006-05-11 |
2012-10-31 |
Isis Pharmaceuticals, Inc. |
5 'modified bicyclic nucleic acid analogs
|
US7812150B2
(en)
|
2006-05-19 |
2010-10-12 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of Aha and therapeutic uses thereof
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
WO2007137301A2
(en)
*
|
2006-05-23 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Modulation of chrebp expression
|
WO2008097328A2
(en)
*
|
2006-06-23 |
2008-08-14 |
Northwestern University |
Asymmetric functionalized nanoparticles and methods of use
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
EP2061799A4
(en)
*
|
2006-09-11 |
2010-12-22 |
Univ Yale |
Methods and compositions for the use of lysine riboswitches
|
CA2663029C
(en)
*
|
2006-09-14 |
2016-07-19 |
Ibis Biosciences, Inc. |
Targeted whole genome amplification method for identification of pathogens
|
WO2008036825A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by rna interference
|
WO2008042156A1
(en)
*
|
2006-09-28 |
2008-04-10 |
Northwestern University |
Maximizing oligonucleotide loading on gold nanoparticle
|
CA2665536C
(en)
|
2006-10-05 |
2016-02-16 |
Massachusetts Institute Of Technology |
Multifunctional encoded particles for high-throughput analysis
|
EP2104516B1
(en)
|
2006-11-01 |
2015-01-07 |
University of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
CA2672297A1
(en)
|
2006-12-11 |
2008-06-19 |
University Of Utah Research Foundation |
Compositions and methods for treating pathologic angiogenesis and vascular permeability
|
EP2913341A1
(en)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
CA2691066C
(en)
|
2007-02-09 |
2018-07-31 |
Northwestern University |
Particles for detecting intracellular targets
|
JP5680304B2
(en)
*
|
2007-02-23 |
2015-03-04 |
アイビス バイオサイエンシズ インコーポレイティッド |
Rapid forensic DNA analysis
|
AU2008227458A1
(en)
|
2007-03-22 |
2008-09-25 |
Yale University |
Methods and compositions related to riboswitches that control alternative splicing
|
US20100204266A1
(en)
*
|
2007-03-23 |
2010-08-12 |
Ibis Biosciences, INC |
Compositions for use in identification of mixed populations of bioagents
|
AP3018A
(en)
|
2007-03-29 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
WO2008156987A2
(en)
|
2007-05-29 |
2008-12-24 |
Yale University |
Riboswitches and methods and compositions for use of and with riboswitches
|
US20100221821A1
(en)
*
|
2007-05-29 |
2010-09-02 |
Yale University |
Methods and compositions related to riboswitches that control alternative splicing and rna processing
|
EP2826863B1
(en)
|
2007-05-30 |
2017-08-23 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
CA2688321A1
(en)
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
WO2008151023A2
(en)
|
2007-06-01 |
2008-12-11 |
Ibis Biosciences, Inc. |
Methods and compositions for multiple displacement amplification of nucleic acids
|
US7807372B2
(en)
*
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
US8278283B2
(en)
*
|
2007-07-05 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
6-disubstituted or unsaturated bicyclic nucleic acid analogs
|
AU2008286771B2
(en)
|
2007-08-15 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
WO2009032693A2
(en)
*
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
WO2009032702A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
US8445217B2
(en)
|
2007-09-20 |
2013-05-21 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
WO2009039442A1
(en)
*
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
US20110152346A1
(en)
*
|
2007-11-05 |
2011-06-23 |
Baltic Technology Development Ltd. |
Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids
|
USRE47320E1
(en)
|
2007-11-20 |
2019-03-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US7845686B2
(en)
*
|
2007-12-17 |
2010-12-07 |
S & B Technical Products, Inc. |
Restrained pipe joining system for plastic pipe
|
EP3100718B1
(en)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
EP2265627A2
(en)
*
|
2008-02-07 |
2010-12-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
WO2009102427A2
(en)
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
CN102014932B
(en)
|
2008-03-05 |
2015-11-25 |
阿尔尼拉姆医药品有限公司 |
For suppressing compositions and the method for Eg5 and VEGF gene expression
|
WO2009117589A1
(en)
*
|
2008-03-21 |
2009-09-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
WO2009124295A2
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
EP2285819B1
(en)
*
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
MX2010011508A
(en)
|
2008-04-18 |
2011-05-03 |
Baxter Int |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes.
|
EP2280995A2
(en)
*
|
2008-04-29 |
2011-02-09 |
Wyeth LLC |
Methods for treating inflammation
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
US20110237646A1
(en)
*
|
2008-08-07 |
2011-09-29 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression for the treatment of cns related disorders
|
EP3081648A1
(en)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
EP2331690B1
(en)
|
2008-09-02 |
2016-01-13 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of mutant egfr gene
|
US8550694B2
(en)
|
2008-09-16 |
2013-10-08 |
Ibis Biosciences, Inc. |
Mixing cartridges, mixing stations, and related kits, systems, and methods
|
WO2010033625A1
(en)
|
2008-09-16 |
2010-03-25 |
Ibis Biosciences, Inc. |
Microplate handling systems and related computer program products and methods
|
WO2010033627A2
(en)
|
2008-09-16 |
2010-03-25 |
Ibis Biosciences, Inc. |
Sample processing units, systems, and related methods
|
US10138485B2
(en)
|
2008-09-22 |
2018-11-27 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
US8604192B2
(en)
*
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
US8501805B2
(en)
*
|
2008-09-24 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-L-bicyclic nucleosides
|
EP2334793B1
(en)
|
2008-09-25 |
2016-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of serum amyloid a gene
|
ES2475065T3
(en)
|
2008-10-09 |
2014-07-10 |
Tekmira Pharmaceuticals Corporation |
Enhanced amino acids and methods for nucleic acid administration
|
AU2009305636A1
(en)
|
2008-10-15 |
2010-04-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of Factor 11 expression
|
NZ592867A
(en)
|
2008-10-20 |
2013-05-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of transthyretin
|
AU2009308217B2
(en)
|
2008-10-24 |
2016-01-21 |
Ionis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
WO2010048585A2
(en)
|
2008-10-24 |
2010-04-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
CA2744207C
(en)
|
2008-11-24 |
2019-05-28 |
Northwestern University |
Polyvalent rna-nanoparticle compositions
|
EP2370451B1
(en)
|
2008-12-02 |
2016-11-16 |
Wave Life Sciences Japan, Inc. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
CN102317458B
(en)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases
|
CA2745811C
(en)
|
2008-12-04 |
2021-07-13 |
Joseph Collard |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
KR101749352B1
(en)
|
2008-12-04 |
2017-06-20 |
큐알엔에이, 인크. |
Treatment of sirtuin 1(sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
EP3225281A1
(en)
|
2008-12-10 |
2017-10-04 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
WO2010080616A1
(en)
|
2008-12-19 |
2010-07-15 |
Abbott Laboratories |
Molecular assay for diagnosis of malaria
|
EP2358905A1
(en)
*
|
2008-12-19 |
2011-08-24 |
Abbott Laboratories |
Diagnostic test for mutations in codons 12-13 of human k-ras
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US20100184844A1
(en)
*
|
2009-01-08 |
2010-07-22 |
Northwestern University |
Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
|
US20100233270A1
(en)
*
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
KR101546673B1
(en)
*
|
2009-01-15 |
2015-08-25 |
삼성전자주식회사 |
Toner for electrophotographic and process for preparing the same
|
CA2750820A1
(en)
|
2009-01-27 |
2010-08-05 |
Qiagen Gaithersburg |
Thermophilic helicase dependent amplification technology with endpoint homogenous fluorescent detection
|
AU2010208035B2
(en)
|
2009-01-29 |
2016-06-23 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
US8536320B2
(en)
|
2009-02-06 |
2013-09-17 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
KR101805199B1
(en)
|
2009-02-12 |
2017-12-05 |
큐알엔에이, 인크. |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
EP3009150B1
(en)
|
2009-02-12 |
2019-11-13 |
CuRNA, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US8158936B2
(en)
*
|
2009-02-12 |
2012-04-17 |
Ibis Biosciences, Inc. |
Ionization probe assemblies
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
US20110319317A1
(en)
|
2009-03-04 |
2011-12-29 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
EP2408920B1
(en)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
US9393564B2
(en)
|
2009-03-30 |
2016-07-19 |
Ibis Biosciences, Inc. |
Bioagent detection systems, devices, and methods
|
KR20120022938A
(en)
|
2009-04-15 |
2012-03-12 |
노오쓰웨스턴 유니버시티 |
Delivery of oligonucleotide-functionalized nanoparticles
|
EP3248618A1
(en)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
ES2661787T3
(en)
|
2009-05-01 |
2018-04-04 |
Curna, Inc. |
Treatment of hemoglobin-related diseases (hbf / hbg) by inhibition of natural antisense transcript for hbf / hbg
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
NZ596186A
(en)
|
2009-05-05 |
2014-03-28 |
Alnylam Pharmaceuticals Inc |
Lipid compositions
|
KR101722541B1
(en)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Treatment of tristetraproline(ttp) related diseases by inhibition of natural antisense transcript to ttp
|
CN103223177B
(en)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
|
WO2010132665A1
(en)
|
2009-05-15 |
2010-11-18 |
Yale University |
Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
|
CN102575251B
(en)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor
|
KR101703695B1
(en)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
EP2435571B1
(en)
|
2009-05-28 |
2016-12-14 |
CuRNA, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
KR101766408B1
(en)
|
2009-06-10 |
2017-08-10 |
알닐람 파마슈티칼스 인코포레이티드 |
Improved lipid formulation
|
EP2443238B1
(en)
|
2009-06-16 |
2017-03-22 |
CuRNA, Inc. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
JP5944311B2
(en)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
Treatment of collagen gene-related diseases by suppression of natural antisense transcripts against collagen genes
|
CN102597238B
(en)
|
2009-06-24 |
2016-06-29 |
库尔纳公司 |
The relevant disease of TNFR2 is treated by suppressing for the natural antisense transcript of tumor necrosis factor receptor 2 (TNFR2)
|
WO2010151674A2
(en)
|
2009-06-26 |
2010-12-29 |
Curna, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
SG177564A1
(en)
|
2009-07-06 |
2012-02-28 |
Ontorii Inc |
Novel nucleic acid prodrugs and methods of use thereof
|
US9194877B2
(en)
|
2009-07-17 |
2015-11-24 |
Ibis Biosciences, Inc. |
Systems for bioagent indentification
|
WO2011008971A1
(en)
*
|
2009-07-17 |
2011-01-20 |
Ibis Biosciences, Inc. |
Lift and mount apparatus
|
WO2011014811A1
(en)
|
2009-07-31 |
2011-02-03 |
Ibis Biosciences, Inc. |
Capture primers and capture sequence linked solid supports for molecular diagnostic tests
|
JP6128848B2
(en)
|
2009-08-05 |
2017-05-17 |
クルナ・インコーポレーテッド |
Treatment of insulin gene (INS) -related diseases by suppression of natural antisense transcripts against the insulin gene (INS)
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
EP2464336A4
(en)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
WO2011022420A1
(en)
|
2009-08-17 |
2011-02-24 |
Yale University |
Methylation biomarkers and methods of use
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US20110091882A1
(en)
*
|
2009-10-02 |
2011-04-21 |
Ibis Biosciences, Inc. |
Determination of methylation status of polynucleotides
|
ES2628739T3
(en)
*
|
2009-10-15 |
2017-08-03 |
Ibis Biosciences, Inc. |
Multiple displacement amplification
|
KR20120099435A
(en)
*
|
2009-10-16 |
2012-09-10 |
립-엑스 파마슈티칼즈, 인크. |
Antimicrobial compounds and methods of making and using the same
|
EA023350B1
(en)
|
2009-10-16 |
2016-05-31 |
Мелинта Терапьютикс, Инк. |
Antimicrobial compounds, methods of making and using the same
|
MX2012004341A
(en)
|
2009-10-16 |
2012-10-05 |
Rib X Pharmaceuticals Inc |
Antimicrobial compounds and methods of making and using the same.
|
CN102711826B
(en)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
For the method and composition that the HEPSIN for regulating and controlling macrophage-stimulating albumen is activated
|
WO2011056687A2
(en)
|
2009-10-27 |
2011-05-12 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
CA2779099C
(en)
|
2009-10-30 |
2021-08-10 |
Northwestern University |
Templated nanoconjugates
|
US20130084565A1
(en)
|
2009-11-03 |
2013-04-04 |
University Of Virginia Patent Foundation |
Versatile, visible method for detecting polymeric analytes
|
AU2010321576A1
(en)
|
2009-11-23 |
2012-06-07 |
Swift Biosciences, Inc. |
Devices to extend single stranded target molecules
|
CA2781887C
(en)
|
2009-11-30 |
2018-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011084455A2
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc. |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
KR101793753B1
(en)
|
2009-12-23 |
2017-11-03 |
큐알엔에이, 인크. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
CN102869776B
(en)
|
2009-12-23 |
2017-06-23 |
库尔纳公司 |
HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF)
|
EP2519633B1
(en)
|
2009-12-29 |
2017-10-25 |
CuRNA, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
NO2521784T3
(en)
|
2010-01-04 |
2018-05-05 |
|
|
US8912157B2
(en)
|
2010-01-06 |
2014-12-16 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
DK2524039T3
(en)
|
2010-01-11 |
2018-03-12 |
Curna Inc |
TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2524042A2
(en)
|
2010-01-12 |
2012-11-21 |
Yale University |
Structured rna motifs and compounds and methods for their use
|
WO2011091390A2
(en)
|
2010-01-25 |
2011-07-28 |
Opko Curna, Llc |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
US20130028889A1
(en)
|
2010-02-04 |
2013-01-31 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
WO2011103528A2
(en)
|
2010-02-22 |
2011-08-25 |
Opko Curna Llc |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
EP2538981B1
(en)
|
2010-02-23 |
2017-12-20 |
F. Hoffmann-La Roche AG |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
US20130101512A1
(en)
|
2010-03-12 |
2013-04-25 |
Chad A. Mirkin |
Crosslinked polynucleotide structure
|
WO2011112732A2
(en)
|
2010-03-12 |
2011-09-15 |
The Brigham And Women's Hospital, Inc. |
Methods of treating vascular inflammatory disorders
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
JP6060071B2
(en)
|
2010-03-24 |
2017-01-11 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
RNA interference in skin and fibrosis applications
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
EP2550000A4
(en)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Reduced size self-delivering rnai compounds
|
WO2011120049A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Integrated Dna Technologies, Inc. |
Methods for enhancing nucleic acid hybridization
|
US9506057B2
(en)
|
2010-03-26 |
2016-11-29 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
US8889350B2
(en)
|
2010-03-26 |
2014-11-18 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
ES2893199T3
(en)
|
2010-03-29 |
2022-02-08 |
Alnylam Pharmaceuticals Inc |
dsRNA therapy for transthyretin (TTR)-related ocular amyloidosis
|
US9044494B2
(en)
|
2010-04-09 |
2015-06-02 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
|
WO2011133695A2
(en)
|
2010-04-20 |
2011-10-27 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
KR101869570B1
(en)
|
2010-04-28 |
2018-06-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Modified nucleosides and oligomeric compounds prepared therefrom
|
EP2625186B1
(en)
|
2010-04-28 |
2016-07-27 |
Ionis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
WO2011139917A1
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
MA34291B1
(en)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
|
EP2566966A4
(en)
|
2010-05-03 |
2013-12-11 |
Curna Inc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
TWI586356B
(en)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
|
CA2799207C
(en)
|
2010-05-26 |
2019-03-26 |
Curna, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
US20130203045A1
(en)
|
2010-05-26 |
2013-08-08 |
University Of Virginia Patent Foundation |
Method for detecting nucleic acids based on aggregate formation
|
WO2011150227A1
(en)
|
2010-05-26 |
2011-12-01 |
Qiagen Gaithersburg, Inc. |
Quantitative helicase assay
|
WO2011153323A2
(en)
|
2010-06-02 |
2011-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
CA2802049C
(en)
|
2010-06-07 |
2018-07-10 |
Firefly Bioworks, Inc. |
Scanning multifunctional particles
|
EP2580228B1
(en)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US9638632B2
(en)
|
2010-06-11 |
2017-05-02 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
WO2011159836A2
(en)
|
2010-06-15 |
2011-12-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
WO2011163466A1
(en)
|
2010-06-23 |
2011-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (nrg-1)
|
US8980860B2
(en)
|
2010-07-14 |
2015-03-17 |
Curna, Inc. |
Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
|
WO2012012467A2
(en)
|
2010-07-19 |
2012-01-26 |
Isis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
US20130143955A1
(en)
|
2010-08-09 |
2013-06-06 |
Yale University |
Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
|
WO2012033848A1
(en)
|
2010-09-07 |
2012-03-15 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
JP5868324B2
(en)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
Asymmetric auxiliary group
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
US20140031250A1
(en)
|
2010-10-07 |
2014-01-30 |
David Tsai Ting |
Biomarkers of Cancer
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
CN103201387B
(en)
|
2010-10-27 |
2018-02-02 |
库尔纳公司 |
IFRD1 relevant diseases are treated by suppressing the natural antisense transcript of interferon correlative development regulatory factor 1 (IFRD1)
|
CN110123830A
(en)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
|
EP3260540A1
(en)
|
2010-11-12 |
2017-12-27 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
EP2640853B1
(en)
|
2010-11-17 |
2018-12-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
WO2012071238A2
(en)
|
2010-11-23 |
2012-05-31 |
Opko Curna Llc |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
WO2012097261A2
(en)
|
2011-01-14 |
2012-07-19 |
The General Hospital Corporation |
Methods targeting mir-128 for regulating cholesterol/lipid metabolism
|
SI2670411T1
(en)
|
2011-02-02 |
2019-06-28 |
Excaliard Pharmaceuticals, Inc. |
Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars
|
EP2670404B1
(en)
|
2011-02-02 |
2018-08-29 |
The Trustees of Princeton University |
Sirtuin modulators as virus production modulators
|
WO2012109157A2
(en)
|
2011-02-07 |
2012-08-16 |
The Governing Council Of The University Of Toronto |
Bioprobes and methods of use thereof
|
EP3467109A1
(en)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
SG193923A1
(en)
|
2011-03-29 |
2013-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
WO2012138453A1
(en)
|
2011-04-03 |
2012-10-11 |
The General Hospital Corporation |
Efficient protein expression in vivo using modified rna (mod-rna)
|
US20140186844A1
(en)
|
2011-04-26 |
2014-07-03 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
RU2620980C2
(en)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Treatment of diseases associated with frataxin (fxn), by inhibiting natural antisense fxn transcript
|
CN112111492A
(en)
|
2011-06-21 |
2020-12-22 |
阿尔尼拉姆医药品有限公司 |
Compositions and methods for inhibiting expression of apolipoprotein C-III (APOC3) gene
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
KR102395085B1
(en)
|
2011-06-21 |
2022-05-09 |
알닐람 파마슈티칼스 인코포레이티드 |
Angiopoietin-like 3(angptl3) irna compostions and methods of use thereof
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
US9222093B2
(en)
|
2011-06-30 |
2015-12-29 |
The University Of Hong Kong |
Two-way, portable riboswitch mediated gene expression control device
|
RU2014105311A
(en)
|
2011-07-19 |
2015-08-27 |
Уэйв Лайф Сайенсес Пте. Лтд. |
METHODS FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
|
EP2739735A2
(en)
|
2011-08-01 |
2014-06-11 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
EP2742136B1
(en)
|
2011-08-11 |
2017-09-27 |
Ionis Pharmaceuticals, Inc. |
Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof
|
DK2751270T3
(en)
|
2011-08-29 |
2018-10-29 |
Ionis Pharmaceuticals Inc |
OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
|
EP2751269B1
(en)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
EP2756080B1
(en)
|
2011-09-14 |
2019-02-20 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
EP2755692B1
(en)
|
2011-09-14 |
2020-11-25 |
Northwestern University |
Nanoconjugates able to cross the blood-brain barrier
|
US9580713B2
(en)
|
2011-09-17 |
2017-02-28 |
Yale University |
Fluoride-responsive riboswitches, fluoride transporters, and methods of use
|
EP2766482B1
(en)
|
2011-10-11 |
2016-12-07 |
The Brigham and Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
ES2687951T3
(en)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anti-HtrA1 antibodies and procedures for use
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
EP2790736B1
(en)
|
2011-12-12 |
2018-01-31 |
Oncoimmunin, Inc. |
In vivo delivery of oligonucleotides
|
WO2013101935A1
(en)
|
2011-12-27 |
2013-07-04 |
Ibis Biosciences, Inc. |
Bioagent detection oligonucleotides
|
WO2013106770A1
(en)
|
2012-01-11 |
2013-07-18 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of ikbkap splicing
|
CN108611398A
(en)
|
2012-01-13 |
2018-10-02 |
Data生物有限公司 |
Genotyping is carried out by new-generation sequencing
|
SG11201405669XA
(en)
|
2012-03-13 |
2014-10-30 |
Swift Biosciences Inc |
Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
|
JP2015511494A
(en)
|
2012-03-15 |
2015-04-20 |
キュアナ,インク. |
Treatment of BDNF-related diseases by inhibition of natural antisense transcripts against brain-derived neurotrophic factor (BDNF)
|
WO2013138662A1
(en)
|
2012-03-16 |
2013-09-19 |
4S3 Bioscience, Inc. |
Antisense conjugates for decreasing expression of dmpk
|
AU2013202595B2
(en)
|
2012-03-30 |
2016-04-21 |
Biogen Ma Inc. |
Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
JP2015518485A
(en)
|
2012-04-20 |
2015-07-02 |
アプタミアール セラピューティクス インコーポレイテッド |
Thermogenic miRNA regulator
|
EP2839006B1
(en)
|
2012-04-20 |
2018-01-03 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
EA201492123A1
(en)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE SMN GENES FAMILY
|
AU2013262663A1
(en)
|
2012-05-16 |
2015-01-22 |
The General Hospital Corporation D/B/A Massachusetts General Hospital |
Compositions and methods for modulating gene expression
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
US9828602B2
(en)
|
2012-06-01 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
WO2013185097A1
(en)
|
2012-06-08 |
2013-12-12 |
The Regents Of The University Of Michigan |
Ultrasound-triggerable agents for tissue engineering
|
SG11201500243WA
(en)
|
2012-07-13 |
2015-04-29 |
Shin Nippon Biomedical Lab Ltd |
Chiral nucleic acid adjuvant
|
US9982257B2
(en)
|
2012-07-13 |
2018-05-29 |
Wave Life Sciences Ltd. |
Chiral control
|
SG11201500239VA
(en)
|
2012-07-13 |
2015-03-30 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
US20140038182A1
(en)
|
2012-07-17 |
2014-02-06 |
Dna Logix, Inc. |
Cooperative primers, probes, and applications thereof
|
WO2014022852A1
(en)
|
2012-08-03 |
2014-02-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
CN104736551B
(en)
|
2012-08-15 |
2017-07-28 |
Ionis制药公司 |
The method for preparing oligomeric compounds using improved end-blocking scheme
|
CA2884245C
(en)
|
2012-09-06 |
2023-03-14 |
The University Of Chicago |
Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
DK2906256T3
(en)
|
2012-10-12 |
2018-11-19 |
Ionis Pharmaceuticals Inc |
SELECTIVE ANTISENSE COMPOUNDS AND APPLICATIONS THEREOF
|
EP4144845A1
(en)
|
2012-10-12 |
2023-03-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
US9695475B2
(en)
|
2012-12-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Competitive modulation of microRNAs
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014121287A2
(en)
|
2013-02-04 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
ES2708650T3
(en)
|
2013-03-14 |
2019-04-10 |
Andes Biotechnologies Global Inc |
Antisense oligonucleotides for the treatment of tumor stem cells
|
KR102605775B1
(en)
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
Complement component c5 irna compositions and methods of use thereof
|
BR112015022621A2
(en)
|
2013-03-14 |
2017-10-31 |
Andes Biotechnologies S A |
methods for detection and treatment of multiple myeloma
|
KR20150130430A
(en)
|
2013-03-14 |
2015-11-23 |
아이시스 파마수티컬즈 인코포레이티드 |
Compositions and methods for modulating tau expression
|
US9347095B2
(en)
|
2013-03-15 |
2016-05-24 |
Bio-Rad Laboratories, Inc. |
Digital assays for mutation detection
|
EP2978446B1
(en)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antibody for use in treating alzheimer's disease
|
WO2014165825A2
(en)
|
2013-04-04 |
2014-10-09 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
WO2015012916A2
(en)
|
2013-04-23 |
2015-01-29 |
Northwestern University |
Metal-ligand coordination polymer nanoparticles and methods for making
|
SG10201906382QA
(en)
|
2013-05-01 |
2019-08-27 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating hbv and ttr expression
|
TWI727917B
(en)
|
2013-05-22 |
2021-05-21 |
美商阿尼拉製藥公司 |
TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
RS57418B1
(en)
|
2013-05-22 |
2018-09-28 |
Alnylam Pharmaceuticals Inc |
Serpina1 irna compositions and methods of use thereof
|
WO2014197835A2
(en)
|
2013-06-06 |
2014-12-11 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
AU2014280847B2
(en)
|
2013-06-13 |
2019-07-04 |
Antisense Therapeutics Ltd |
Combination therapy
|
CA2916252A1
(en)
|
2013-06-21 |
2014-12-24 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
EP3022176B8
(en)
|
2013-07-15 |
2019-12-25 |
The Regents of the University of California |
Azacyclic constrained analogs of fty720
|
TWI657819B
(en)
|
2013-07-19 |
2019-05-01 |
美商Ionis製藥公司 |
Compositions for modulating tau expression
|
US10435430B2
(en)
|
2013-07-31 |
2019-10-08 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
GB201313897D0
(en)
*
|
2013-08-02 |
2013-09-18 |
Maersk Olie & Gas |
Conformance control in enhanced oil recovery
|
ES2773547T3
(en)
|
2013-08-08 |
2020-07-13 |
Scripps Research Inst |
An in vitro nucleic acid site specific enzymatic labeling procedure by incorporating unnatural nucleotides
|
TW201536329A
(en)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
|
MX2016003046A
(en)
|
2013-09-09 |
2016-09-08 |
Melinta Therapeutics Inc |
Antimicrobial compounds and methods of making and using the same.
|
CN106103442A
(en)
|
2013-09-09 |
2016-11-09 |
梅琳塔治疗公司 |
Its method of Antimicrobe compound and preparation and use
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
CN105793423A
(en)
|
2013-10-02 |
2016-07-20 |
阿尔尼拉姆医药品有限公司 |
Compositions and methods for inhibiting expression of the LECT2 gene
|
JP6613227B2
(en)
|
2013-10-04 |
2019-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Composition and method for inhibiting the expression of ALAS1 gene
|
WO2015054451A1
(en)
|
2013-10-09 |
2015-04-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
CN105899679A
(en)
|
2013-10-21 |
2016-08-24 |
通用医疗公司 |
Methods relating to circulating tumor cell clusters and the treatment of cancer
|
WO2015066708A1
(en)
|
2013-11-04 |
2015-05-07 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
|
US10752940B2
(en)
|
2013-11-08 |
2020-08-25 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for detecting oligonucleotides
|
ES2797679T3
(en)
|
2013-12-02 |
2020-12-03 |
Ionis Pharmaceuticals Inc |
Antisense compounds and their uses
|
US10934550B2
(en)
|
2013-12-02 |
2021-03-02 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer
|
WO2015126502A2
(en)
|
2013-12-03 |
2015-08-27 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
US10385388B2
(en)
|
2013-12-06 |
2019-08-20 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
IL282401B
(en)
|
2013-12-12 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
CN111729090A
(en)
|
2013-12-20 |
2020-10-02 |
通用医疗公司 |
Methods and assays relating to circulating tumor cells
|
US10149905B2
(en)
|
2014-01-15 |
2018-12-11 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
JPWO2015108046A1
(en)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action
|
JPWO2015108047A1
(en)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator
|
DK3094728T3
(en)
|
2014-01-16 |
2022-05-16 |
Wave Life Sciences Ltd |
KIRALT DESIGN
|
EP3102197B1
(en)
|
2014-02-04 |
2018-08-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2015123264A1
(en)
|
2014-02-11 |
2015-08-20 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
EP3119789B1
(en)
|
2014-03-17 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
RU2019130898A
(en)
|
2014-03-19 |
2019-11-11 |
Ионис Фармасьютикалз, Инк. |
COMPOSITIONS FOR MODULATION OF ATAXIN 2 EXPRESSION
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
RU2704619C2
(en)
|
2014-04-01 |
2019-10-30 |
Биоген Ма Инк. |
Compositions for modulating expression of sod-1
|
EP3943607A1
(en)
|
2014-04-09 |
2022-01-26 |
The Scripps Research Institute |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
DK3137476T3
(en)
|
2014-04-28 |
2019-11-18 |
Ionis Pharmaceuticals Inc |
LINKER-MODIFIED OLIGOMER COMPOUNDS
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
SI3137605T1
(en)
|
2014-05-01 |
2021-02-26 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
EP3137604B1
(en)
|
2014-05-01 |
2020-07-15 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
SG11201608502TA
(en)
|
2014-05-01 |
2016-11-29 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating complement factor b expression
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
EA201692370A1
(en)
|
2014-05-22 |
2017-03-31 |
Элнилэм Фармасьютикалз, Инк. |
COMPOSITIONS of mRNA ANGIOTENZINOGENA (AGT) AND METHODS OF THEIR USE
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
BR112016028211A2
(en)
|
2014-06-02 |
2017-10-24 |
Childrens Medical Center |
methods and compositions for immunomodulation
|
CN106661580B
(en)
|
2014-06-10 |
2022-02-15 |
鹿特丹伊拉斯谟大学医疗中心 |
Antisense oligonucleotides for treating pompe disease
|
CN106414738A
(en)
|
2014-06-24 |
2017-02-15 |
雅培分子公司 |
Detection of single nucleotide polymorphisms in human kras
|
EP3161159B1
(en)
|
2014-06-25 |
2020-08-05 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
US9951327B1
(en)
|
2014-07-17 |
2018-04-24 |
Integrated Dna Technologies, Inc. |
Efficient and rapid method for assembling and cloning double-stranded DNA fragments
|
MX2017001432A
(en)
|
2014-07-31 |
2017-05-09 |
Uab Res Found |
Apoe mimetic peptides and higher potency to clear plasma cholesterol.
|
CA2958431A1
(en)
|
2014-08-19 |
2016-02-25 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
CN107074767A
(en)
|
2014-08-20 |
2017-08-18 |
西北大学 |
Unlimited coordination polymer nano particle-nucleic acid conjugate of the bio-compatible adjusted for antisense gene
|
CN107106704A
(en)
|
2014-08-29 |
2017-08-29 |
儿童医疗中心有限公司 |
Method and composition for treating cancer
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016033326A2
(en)
|
2014-08-29 |
2016-03-03 |
Alnylam Pharmaceuticals, Inc. |
Methods of treating transthyretin (ttr) mediated amyloidosis
|
KR102506169B1
(en)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
EP3198012B1
(en)
|
2014-09-26 |
2019-09-04 |
University of Massachusetts |
Rna-modulating agents
|
JOP20200115A1
(en)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
|
EP3207138B1
(en)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3212794B1
(en)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(en)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2016077540A1
(en)
|
2014-11-12 |
2016-05-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of comp
|
CN107250362B
(en)
|
2014-11-17 |
2021-10-22 |
阿尔尼拉姆医药品有限公司 |
Apolipoprotein C3(APOC3) iRNA compositions and methods of use thereof
|
CN107106493A
(en)
|
2014-11-21 |
2017-08-29 |
西北大学 |
The sequence-specific cellular uptake of spherical nucleic acid nano particle conjugate
|
EP3229842B1
(en)
|
2014-12-08 |
2022-07-06 |
The Board of Regents of The University of Texas System |
Lipocationic polymers and uses thereof
|
JP6997623B2
(en)
|
2014-12-12 |
2022-02-04 |
エム. ウルフ、トッド |
Compositions and Methods for Editing Intracellular Nucleic Acids Utilizing Oligonucleotides
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
JP2018506715A
(en)
|
2015-01-23 |
2018-03-08 |
ヴァンダービルト ユニバーシティー |
Robust interferometer and method of use
|
EP3256487A4
(en)
|
2015-02-09 |
2018-07-18 |
Duke University |
Compositions and methods for epigenome editing
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP3262173A2
(en)
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
EA201792006A1
(en)
|
2015-03-11 |
2018-04-30 |
Мелинта Терапьютикс, Инк. |
ANTIMICROBIAL COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND THEIR APPLICATION
|
MX2017012407A
(en)
|
2015-03-27 |
2018-03-07 |
Harvard College |
Modified t cells and methods of making and using the same.
|
WO2016164463A1
(en)
|
2015-04-07 |
2016-10-13 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive x chromosome
|
PL3283500T3
(en)
|
2015-04-08 |
2021-05-31 |
The University Of Chicago |
Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
CN108139375A
(en)
|
2015-06-26 |
2018-06-08 |
贝斯以色列女执事医疗中心股份有限公司 |
Target the cancer therapy for inhibiting the four transmembrane proteins 33 (TSPAN33) in cell derived from marrow sample
|
EP3314027A4
(en)
|
2015-06-29 |
2019-07-03 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
EP3313989A4
(en)
|
2015-06-29 |
2018-12-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
MY192997A
(en)
|
2015-07-10 |
2022-09-20 |
Ionis Pharmaceuticals Inc |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
MA43072A
(en)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
CA2993652A1
(en)
|
2015-07-28 |
2017-02-02 |
Caris Science, Inc. |
Targeted oligonucleotides
|
WO2017021961A1
(en)
|
2015-08-04 |
2017-02-09 |
Yeda Research And Development Co. Ltd. |
Methods of screening for riboswitches and attenuators
|
CN114525280A
(en)
|
2015-09-02 |
2022-05-24 |
阿尔尼拉姆医药品有限公司 |
iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof
|
CN108271360B
(en)
|
2015-09-14 |
2023-01-24 |
得克萨斯州大学系统董事会 |
Lipophilic cationic dendritic polymer and use thereof
|
AU2016339053A1
(en)
|
2015-09-24 |
2018-04-12 |
Crispr Therapeutics Ag |
Novel family of RNA-programmable endonucleases and their uses in genome editing and other applications
|
RU2018113709A
(en)
|
2015-09-24 |
2019-10-30 |
Айонис Фармасьютикалз, Инк. |
KRAS EXPRESSION MODULATORS
|
CA2999177A1
(en)
|
2015-09-24 |
2017-03-30 |
The Regents Of The University Of California |
Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
|
WO2017053781A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
WO2017058672A1
(en)
|
2015-09-29 |
2017-04-06 |
The Regents Of The University Of Michigan Office Of Technology Transfer |
Biodegradable hydrogel for tissue expansion
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
JP2018531037A
(en)
|
2015-10-19 |
2018-10-25 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAs
|
EP3368063B1
(en)
|
2015-10-28 |
2023-09-06 |
Vertex Pharmaceuticals Inc. |
Materials and methods for treatment of duchenne muscular dystrophy
|
SI3368578T1
(en)
|
2015-10-30 |
2021-08-31 |
F. Hoffmann-La Roche Ag |
Anti-htra1 antibodies and methods of use thereof
|
WO2017075670A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
PE20181180A1
(en)
|
2015-11-06 |
2018-07-20 |
Ionis Pharmaceuticals Inc |
MODULATE THE EXPRESSION OF APOLIPOPROTEIN (a)
|
BR112018008971A2
(en)
|
2015-11-06 |
2018-11-27 |
Crispr Therapeutics Ag |
Materials and Methods for Treatment of Type 1a Glycogen Storage Disease
|
US20190046555A1
(en)
|
2015-11-06 |
2019-02-14 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
EP3967758A1
(en)
|
2015-12-01 |
2022-03-16 |
CRISPR Therapeutics AG |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
AU2015416656B2
(en)
|
2015-12-07 |
2023-02-23 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for Pompe disease
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
AU2016376191A1
(en)
|
2015-12-23 |
2018-07-12 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
WO2017132483A1
(en)
|
2016-01-29 |
2017-08-03 |
Vanderbilt University |
Free-solution response function interferometry
|
WO2017134529A1
(en)
|
2016-02-02 |
2017-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
US20190112353A1
(en)
|
2016-02-18 |
2019-04-18 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
JP7033072B2
(en)
|
2016-02-25 |
2022-03-09 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
Treatment for fibrosis targeting SMOC2
|
CA3016592A1
(en)
|
2016-03-04 |
2017-09-08 |
Rhode Island Hospital |
Targeting microrna for cancer treatment
|
US11136577B2
(en)
|
2016-03-09 |
2021-10-05 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting PMP22 expression
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
WO2017158422A1
(en)
|
2016-03-16 |
2017-09-21 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hereditary haemochromatosis
|
JP2019516393A
(en)
|
2016-03-18 |
2019-06-20 |
カリス サイエンス インコーポレイテッド |
Oligonucleotide probes and uses thereof
|
ES2933435T3
(en)
|
2016-04-13 |
2023-02-08 |
Ionis Pharmaceuticals Inc |
Methods to reduce the expression of C9ORF72
|
AU2017252023A1
(en)
|
2016-04-18 |
2018-11-15 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
MA45295A
(en)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
CN109414408B
(en)
|
2016-05-16 |
2022-03-29 |
得克萨斯州大学系统董事会 |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
WO2017205686A1
(en)
|
2016-05-25 |
2017-11-30 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
US11708614B2
(en)
|
2016-06-15 |
2023-07-25 |
Streck Llc |
Assays and methods for determining microbial resistance
|
EP3471781A4
(en)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
WO2017223528A1
(en)
|
2016-06-24 |
2017-12-28 |
The Scripps Research Institute |
Novel nucleoside triphosphate transporter and uses thereof
|
WO2018002812A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
WO2018002783A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
EP3481856A1
(en)
|
2016-07-06 |
2019-05-15 |
Crispr Therapeutics AG |
Materials and methods for treatment of pain related disorders
|
AU2017292173B2
(en)
|
2016-07-06 |
2022-01-13 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
US11253601B2
(en)
|
2016-07-11 |
2022-02-22 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
RS63928B1
(en)
|
2016-07-15 |
2023-02-28 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulation of smn2
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
SG10201607303YA
(en)
|
2016-09-01 |
2018-04-27 |
Agency Science Tech & Res |
Antisense oligonucleotides to induce exon skipping
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
JOP20190065A1
(en)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing tau expression
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
SG10201609048RA
(en)
|
2016-10-28 |
2018-05-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
CA3037046A1
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
JOP20190104A1
(en)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn3 expression
|
TWI788312B
(en)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
EP3555296A4
(en)
|
2016-12-13 |
2020-07-29 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
KR20230166146A
(en)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
Methods for treating or preventing ttr-associated diseases using transthyretin(ttr) irna compositions
|
IL301053A
(en)
|
2017-01-23 |
2023-05-01 |
Regeneron Pharma |
Hsd17b13 variants and uses thereof
|
CA3054031A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
EP3585900B1
(en)
|
2017-02-22 |
2022-12-21 |
CRISPR Therapeutics AG |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
US11407997B2
(en)
|
2017-02-22 |
2022-08-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
|
EP3585807A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
JOP20190215A1
(en)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
Modulators of pcsk9 expression
|
US20180284123A1
(en)
|
2017-03-30 |
2018-10-04 |
California Institute Of Technology |
Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
|
US11203611B2
(en)
|
2017-04-14 |
2021-12-21 |
Tollnine, Inc. |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
AU2018254437A1
(en)
|
2017-04-18 |
2019-11-28 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis B virus (HBV) infection
|
WO2018193428A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
JP2020517613A
(en)
|
2017-04-20 |
2020-06-18 |
シンセナ アーゲー |
Modified oligomeric compounds containing tricyclo DNA nucleosides and uses thereof
|
EP3612232A1
(en)
|
2017-04-21 |
2020-02-26 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
US11622977B2
(en)
|
2017-05-12 |
2023-04-11 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
EP3645546A4
(en)
|
2017-06-30 |
2021-12-01 |
Solstice Biologics, Ltd. |
Chiral phosphoramidite auxiliaries and methods of their use
|
CN111051512A
(en)
|
2017-07-11 |
2020-04-21 |
辛索克斯公司 |
Incorporation of non-natural nucleotides and methods thereof
|
WO2019014530A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
EP3652186A4
(en)
|
2017-07-13 |
2021-03-31 |
Northwestern University |
General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
|
WO2019028425A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of autoimmune diseases
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
US11806360B2
(en)
|
2017-09-19 |
2023-11-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
|
SG11202003464VA
(en)
|
2017-10-17 |
2020-05-28 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing for hemophilia a
|
US20210180091A1
(en)
|
2017-10-26 |
2021-06-17 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
TWI809004B
(en)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
Compounds and methods for reducing snca expression
|
US20210032622A1
(en)
|
2017-11-09 |
2021-02-04 |
Crispr Therapeutics Ag |
Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
EP3714054A1
(en)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
CN111727251A
(en)
|
2017-11-21 |
2020-09-29 |
克里斯珀医疗股份公司 |
Materials and methods for treating autosomal dominant retinitis pigmentosa
|
US20200384033A1
(en)
|
2017-12-05 |
2020-12-10 |
Vertex Pharmaceuticals Incorporated |
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
|
CA3084825A1
(en)
|
2017-12-14 |
2019-06-20 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
WO2019118916A1
(en)
|
2017-12-14 |
2019-06-20 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
AU2018388484A1
(en)
|
2017-12-18 |
2020-07-30 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (HMGB1) iRNA compositions and methods of use thereof
|
AU2018393050A1
(en)
|
2017-12-21 |
2020-06-18 |
Bayer Healthcare Llc |
Materials and methods for treatment of Usher Syndrome Type 2A
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
EP3728595A1
(en)
|
2017-12-21 |
2020-10-28 |
CRISPR Therapeutics AG |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
CA3088180A1
(en)
|
2018-01-12 |
2019-07-18 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting transferrin
|
WO2019140231A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
MX2020007369A
(en)
|
2018-01-15 |
2020-10-28 |
Ionis Pharmaceuticals Inc |
Modulators of dnm2 expression.
|
WO2019142135A1
(en)
|
2018-01-19 |
2019-07-25 |
Synthena Ag |
Tricyclo-dna nucleoside precursors and processes for preparing the same
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
MA51787A
(en)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
SUBSTANCES AND METHODS OF TREATMENT OF HEMOGLOBINOPATHIES
|
MA51788A
(en)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
SUBSTANCES AND METHODS FOR TREATING HEMOGLOBINOPATHIES
|
JP7317029B2
(en)
|
2018-02-12 |
2023-07-28 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Modified compounds and uses thereof
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
KR20200127207A
(en)
|
2018-02-26 |
2020-11-10 |
신톡스, 인크. |
IL-15 conjugate and uses thereof
|
TW202000199A
(en)
|
2018-03-02 |
2020-01-01 |
美商Ionis製藥公司 |
Modulators of IRF4 expression
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
EP3768834A1
(en)
|
2018-03-19 |
2021-01-27 |
CRISPR Therapeutics AG |
Novel rna-programmable endonuclease systems and uses thereof
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
EP4051799A2
(en)
|
2018-03-30 |
2022-09-07 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Aptamers for targeted activaton of t cell-mediated immunity
|
CN116536272A
(en)
|
2018-04-06 |
2023-08-04 |
儿童医疗中心有限公司 |
Compositions and methods for somatic reprogramming and imprinting
|
SG11202008660TA
(en)
|
2018-04-11 |
2020-10-29 |
Ionis Pharmaceuticals Inc |
Modulators of ezh2 expression
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
WO2019213571A1
(en)
|
2018-05-03 |
2019-11-07 |
The Trustees Of Wheaton College |
Improved membranes for nanopore sensing applications
|
CR20200604A
(en)
|
2018-05-09 |
2021-02-09 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn3 expression
|
BR112020020957B1
(en)
|
2018-05-09 |
2022-05-10 |
Ionis Pharmaceuticals, Inc |
Oligomeric compounds, population and pharmaceutical composition thereof and their uses
|
TW202016304A
(en)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
US11833168B2
(en)
|
2018-06-14 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
US11332746B1
(en)
|
2018-06-27 |
2022-05-17 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing LRRK2 expression
|
MX2021000922A
(en)
|
2018-07-25 |
2021-03-31 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn2 expression.
|
BR112021001613A2
(en)
|
2018-08-13 |
2021-05-04 |
Alnylam Pharmaceuticals, Inc. |
double-stranded ribonucleic acid agents, cell, pharmaceutical compositions, methods of inhibiting gene expression, inhibiting replication and treating a subject, methods for reducing the level of an antigen and for reducing viral load, and use of an agent dsrna
|
US20210348162A1
(en)
|
2018-08-16 |
2021-11-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
AU2019325255A1
(en)
|
2018-08-20 |
2021-04-15 |
Rogcon, Inc. |
Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
|
US20210292766A1
(en)
|
2018-08-29 |
2021-09-23 |
University Of Massachusetts |
Inhibition of Protein Kinases to Treat Friedreich Ataxia
|
EP3620520A1
(en)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Novel target to treat a metabolic disease in an individual
|
US20220056220A1
(en)
|
2018-09-14 |
2022-02-24 |
Northwestern University |
Programming protein polymerization with dna
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202023573A
(en)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Modulators of pnpla3 expression
|
US20210348159A1
(en)
|
2018-10-17 |
2021-11-11 |
Crispr Therapeutics Ag |
Compositions and methods for delivering transgenes
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
TW202028222A
(en)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Modulators of foxp3 expression
|
BR112021008967A2
(en)
|
2018-11-15 |
2021-08-17 |
Ionis Pharmaceuticals, Inc. |
irf5 expression modulators
|
TW202039841A
(en)
|
2018-11-21 |
2020-11-01 |
美商Ionis製藥公司 |
Compounds and methods for reducing prion expression
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
EP4285929A3
(en)
|
2018-12-20 |
2024-03-06 |
Humabs Biomed SA |
Combination hbv therapy
|
WO2020132521A1
(en)
|
2018-12-20 |
2020-06-25 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
KR20210117271A
(en)
|
2018-12-21 |
2021-09-28 |
노쓰웨스턴유니버시티 |
Use of annexin to prevent and treat myofascial injuryUse of annexin to prevent and treat muscle damage
|
WO2020139977A1
(en)
|
2018-12-26 |
2020-07-02 |
Northwestern University |
Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
|
SG11202107669WA
(en)
|
2019-01-16 |
2021-08-30 |
Genzyme Corp |
Serpinc1 irna compositions and methods of use thereof
|
JP2022519532A
(en)
|
2019-01-31 |
2022-03-24 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Modulator of YAP1 expression
|
AU2020218203A1
(en)
|
2019-02-06 |
2021-08-26 |
Synthorx, Inc. |
IL-2 conjugates and methods of use thereof
|
MA54951A
(en)
|
2019-02-15 |
2021-12-22 |
Bayer Healthcare Llc |
GENE EDITING FOR HEMOPHILIA A WITH ENHANCED FACTOR VIII EXPRESSION
|
AU2020227824A1
(en)
|
2019-02-27 |
2021-08-26 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
US20220175956A1
(en)
|
2019-03-06 |
2022-06-09 |
Northwestern University |
Hairpin-like oligonucleotide-conjugated spherical nucleic acid
|
CA3139919A1
(en)
|
2019-03-11 |
2020-09-17 |
Ochsner Health System |
Microrna regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage
|
SG11202109741VA
(en)
|
2019-03-12 |
2021-10-28 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
WO2020205463A1
(en)
|
2019-03-29 |
2020-10-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating ube3a-ats
|
BR112021022806A2
(en)
|
2019-05-13 |
2022-01-25 |
Vir Biotechnology Inc |
Method for treating chronic hbv infection, sirna, uses of a sirna, and of a sirna and peg-ifna and of a sirna, peg-ifna and an nrti, method, composition for use or use and kit
|
WO2020243644A1
(en)
|
2019-05-31 |
2020-12-03 |
Streck, Inc. |
Detection of antibiotic resistance genes
|
US11879145B2
(en)
|
2019-06-14 |
2024-01-23 |
The Scripps Research Institute |
Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
|
EP3956450A4
(en)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
CN114555128A
(en)
|
2019-08-15 |
2022-05-27 |
新索思股份有限公司 |
Combination immunooncology therapy with IL-2 conjugates
|
EP4013767A4
(en)
|
2019-08-15 |
2023-10-25 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds and uses thereof
|
KR20220051355A
(en)
|
2019-08-23 |
2022-04-26 |
신톡스, 인크. |
IL-15 conjugates and uses thereof
|
EP4025694A1
(en)
|
2019-09-03 |
2022-07-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
WO2021050554A1
(en)
|
2019-09-10 |
2021-03-18 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
JP2022552249A
(en)
|
2019-10-14 |
2022-12-15 |
アストラゼネカ・アクチエボラーグ |
Modulators of PNPLA3 expression
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
AU2020369515A1
(en)
|
2019-10-22 |
2022-04-21 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
WO2021086623A1
(en)
|
2019-10-31 |
2021-05-06 |
The Trustees Of Wheaton College |
Design and characterization of multilayered structures for support of lipid bilayers
|
EP4051796A1
(en)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
TW202132567A
(en)
|
2019-11-01 |
2021-09-01 |
美商阿尼拉製藥公司 |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
JP2022554272A
(en)
|
2019-11-04 |
2022-12-28 |
シンソークス, インコーポレイテッド |
Interleukin 10 conjugates and uses thereof
|
WO2021096763A1
(en)
|
2019-11-13 |
2021-05-20 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
US20230056569A1
(en)
|
2019-11-22 |
2023-02-23 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
JP2023503635A
(en)
|
2019-11-27 |
2023-01-31 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフト |
Methods of synthesizing RNA molecules
|
MX2022006433A
(en)
|
2019-12-13 |
2022-06-23 |
Alnylam Pharmaceuticals Inc |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof.
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP4077674A1
(en)
|
2019-12-18 |
2022-10-26 |
Alia Therapeutics S.R.L. |
Compositions and methods for treating retinitis pigmentosa
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
CN115427571A
(en)
|
2020-02-10 |
2022-12-02 |
阿尔尼拉姆医药品有限公司 |
Compositions and methods for silencing VEGF-A expression
|
MX2022010052A
(en)
|
2020-02-18 |
2022-09-05 |
Alnylam Pharmaceuticals Inc |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof.
|
TW202140787A
(en)
|
2020-02-28 |
2021-11-01 |
美商Ionis製藥公司 |
Compounds and methods for modulating smn2
|
CA3169523A1
(en)
|
2020-02-28 |
2021-09-02 |
Jaume Pons |
Transglutaminase-mediated conjugation
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
CA3174725A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
EP4121534A1
(en)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
US20230295622A1
(en)
|
2020-04-06 |
2023-09-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
CN116134135A
(en)
|
2020-04-07 |
2023-05-16 |
阿尔尼拉姆医药品有限公司 |
Compositions and methods for silencing SCN9A expression
|
EP4133077A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
BR112022021813A2
(en)
|
2020-04-27 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
APOLIPOPROTEIN AND (APOE) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
IL297680A
(en)
|
2020-04-30 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
Complement factor b (cfb) irna compositions and methods of use thereof
|
EP4143321A2
(en)
|
2020-05-01 |
2023-03-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating atxn1
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
EP4150087A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
AR122534A1
(en)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
BR112022024420A2
(en)
|
2020-06-18 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
CA3182458A1
(en)
|
2020-06-24 |
2021-12-30 |
Laura ROSEN |
Engineered hepatitis b virus neutralizing antibodies and uses thereof
|
AU2021296622A1
(en)
|
2020-06-25 |
2023-02-23 |
Synthorx, Inc. |
Immuno oncology combination therapy with IL-2 conjugates and anti-EGFR antibodies
|
JP2023532518A
(en)
|
2020-06-29 |
2023-07-28 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Compounds and methods for modulating PLP1
|
TW202227102A
(en)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
Method of treating fatty liver disease
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
US20230392134A1
(en)
|
2020-09-30 |
2023-12-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
TW202229552A
(en)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
EP3978608A1
(en)
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
|
BR112023006024A2
(en)
|
2020-10-09 |
2023-05-09 |
Synthorx Inc |
IMMUNO-ONCOLOGY THERAPIES WITH IL-2 CONJUGATES
|
MX2023004029A
(en)
|
2020-10-09 |
2023-04-27 |
Synthorx Inc |
Immuno oncology combination therapy with il-2 conjugates and pembrolizumab.
|
EP4232581A1
(en)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
JP2023549500A
(en)
|
2020-11-13 |
2023-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Coagulation factor V (F5) iRNA composition and method of use thereof
|
US11447521B2
(en)
|
2020-11-18 |
2022-09-20 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
CA3202708A1
(en)
|
2020-11-23 |
2022-05-27 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
CA3201452A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
EP4259795A1
(en)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
BR112023012377A2
(en)
|
2020-12-23 |
2023-10-24 |
Flagship Pioneering Innovations Vi Llc |
MODIFIED TRAIN COMPOSITIONS AND USES THEREOF
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2022174102A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
TW202305131A
(en)
|
2021-02-12 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES
|
TW202245843A
(en)
|
2021-02-12 |
2022-12-01 |
美商欣爍克斯公司 |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
CN117222739A
(en)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
Prion protein (PRNP) IRNA compositions and methods of use thereof
|
WO2022182574A1
(en)
|
2021-02-26 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2022231003A1
(en)
|
2021-03-04 |
2023-09-14 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
US20220288181A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
JP2024512635A
(en)
|
2021-03-29 |
2024-03-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Huntingtin (HTT) iRNA agent composition and method of use thereof
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
TW202309291A
(en)
|
2021-04-07 |
2023-03-01 |
法商新植物Sas公司 |
Compositions and methods for indoor air remediation
|
KR20240001207A
(en)
|
2021-04-26 |
2024-01-03 |
알닐람 파마슈티칼스 인코포레이티드 |
Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of using the same
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
EP4334448A1
(en)
|
2021-05-03 |
2024-03-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
TW202313679A
(en)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
Head and neck cancer combination therapy comprising an il-2 conjugate and a pd-1 antagonist
|
WO2022256290A2
(en)
|
2021-06-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
AR126070A1
(en)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4)
|
EP4101928A1
(en)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Type v rna programmable endonuclease systems
|
KR20240021218A
(en)
|
2021-06-11 |
2024-02-16 |
바이엘 악티엔게젤샤프트 |
Novel type V RNA programmable endonuclease system
|
CN117500815A
(en)
|
2021-06-18 |
2024-02-02 |
Ionis制药公司 |
Compounds and methods for reducing IFNAR1 expression
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
CA3225469A1
(en)
|
2021-06-30 |
2023-01-05 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
WO2023285431A1
(en)
|
2021-07-12 |
2023-01-19 |
Alia Therapeutics Srl |
Compositions and methods for allele specific treatment of retinitis pigmentosa
|
IL309905A
(en)
|
2021-07-23 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
IL310244A
(en)
|
2021-08-03 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Transthyretin (ttr) irna compositions and methods of use thereof
|
CA3228255A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing angiotensinogen (agt)
|
AU2022328347A1
(en)
|
2021-08-13 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (f12) irna compositions and methods of use thereof
|
WO2023034870A2
(en)
|
2021-09-01 |
2023-03-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing dmpk expression
|
EP4144841A1
(en)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023056329A1
(en)
|
2021-09-30 |
2023-04-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
TW202334418A
(en)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
WO2023076451A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023086292A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
WO2023086295A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023118349A1
(en)
|
2021-12-21 |
2023-06-29 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024056880A2
(en)
|
2022-09-16 |
2024-03-21 |
Alia Therapeutics Srl |
Enqp type ii cas proteins and applications thereof
|